Login to Your Account



CRT, Merck Serono Ink Deal for Drugs to Block WNT Signal

By Nuala Moran
Staff Writer

Monday, August 5, 2013
LONDON – Cancer Research Technology Ltd. (CRT) agreed to its third licensing deal in six weeks, signing up Merck Serono SA to take forward compounds that block the WNT cell-signaling pathway.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription